Article
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Dec 2024
Lu S, Ahn M-J, Reungwetwattana T, Özgüroğlu M, Kato T, Yang J C-H, Huang M, Fujiki F, Inoue T, Quang L-V, Sriuranpong V, Vicente D, Fuentes C, Chaudhry A A, Poole L, Armenteros Monterroso E, Rukazenkov Y, van der Gronde T, Ramalingam S S
Abstract excerpt
BACKGROUND: Distant metastases in non-small-cell lung cancer (NSCLC) are a poor prognostic factor that negatively impact quality of life. The central nervous system (CNS) is a common site of distant progression in epidermal growth factor receptor-mutated (EGFRm) NSCLC. Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor recommended for advanced EGFRm NSCLC and as adjuvant treatment for resected EGFRm...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.